Profile data is unavailable for this security.
About the company
Biodesix, Inc. (Biodesix) is a diagnostic solutions and services company. The Company develops diagnostic tests addressing clinical questions by combining multi-omics through the power of artificial intelligence. Biodesix offers over five Medicare-covered tests for patients with lung diseases. The blood based Nodify Lung Nodule Risk Assessment testing strategy, consisting of the Nodify XL2 and the Nodify CDT tests, evaluates the risk of malignancy in incidental pulmonary nodules, enabling physicians to better triage patients to the appropriate course of action. The blood based IQLung strategy for lung cancer patients integrates the GeneStrat targeted ddPCR test, the GeneStrat NGS test and the VeriStrat test to support treatment decisions across all stages of lung cancer. Biodesix also leverages the advanced Diagnostic Cortex artificial intelligence (AI) platform, to collaborate with biotechnology and pharmaceutical companies to solve complex diagnostic challenges in lung disease.
- Revenue in USD (TTM)65.56m
- Net income in USD-43.82m
- Incorporated2005
- Employees217.00
- LocationBiodesix Inc919 West Dillon RoadLOUISVILLE 80027United StatesUSA
- Phone+1 (303) 417-0500
- Fax+1 (303) 417-9700
- Websitehttps://www.biodesix.com/
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cardiff Lexington Corp | 7.22m | -2.84m | 97.74m | 10.00 | 0.7895 | -- | -- | 13.54 | 8.23 | 3.61 | 0.9605 | 0.5838 | 0.3436 | -- | 0.542 | 722,096.00 | -9.27 | -- | -25.14 | -- | 49.32 | 62.01 | -26.98 | -- | -- | -0.0099 | 0.4916 | -- | -- | 39.71 | -- | -- | -- | -- |
| American Well Corp | 254.04m | -214.08m | 122.71m | 1.10k | -- | 0.3637 | -- | 0.483 | -14.54 | -14.54 | 17.22 | 22.02 | 0.4545 | 26.31 | 3.74 | 230,104.20 | -38.46 | -28.25 | -49.63 | -32.66 | 34.80 | 40.51 | -84.63 | -121.27 | 2.88 | -- | 0.00 | -- | -6.55 | 17.85 | -149.66 | -- | 51.49 | -- |
| Zomedica Corp | 26.73m | -62.19m | 128.57m | 144.00 | -- | 0.6338 | -- | 4.81 | -0.0635 | -0.0635 | 0.0273 | 0.207 | 0.1093 | 1.77 | 14.31 | 185,604.20 | -25.43 | -14.03 | -26.22 | -14.45 | 69.64 | -- | -232.70 | -220.98 | 10.15 | -- | 0.00 | -- | 33.05 | -- | -102.93 | -- | 89.85 | -- |
| Longduoduo Co Ltd | 7.39m | 1.26m | 150.33m | 49.00 | 119.74 | 213.98 | 102.59 | 20.34 | 0.0418 | 0.0418 | 0.2463 | 0.0234 | 4.17 | 422.80 | 61.99 | 150,812.90 | 76.89 | -- | 1,467.79 | -- | 97.65 | -- | 18.45 | -- | 1.31 | -- | 0.00 | -- | 93.52 | -- | 3,311.69 | -- | -- | -- |
| Nutex Health Inc | 292.00m | -41.13m | 173.39m | 800.00 | -- | 2.75 | -- | 0.5938 | -8.93 | -8.93 | 60.20 | 11.59 | 0.6361 | 90.72 | 4.82 | 365,000.50 | -7.06 | -69.35 | -8.65 | -84.85 | 23.24 | 10.97 | -11.10 | -102.85 | 1.74 | 1.44 | 0.7824 | -- | 12.93 | 428.22 | 89.22 | -- | -- | -- |
| Joint Corp | 120.80m | -16.86m | 173.51m | 444.00 | -- | 8.46 | -- | 1.44 | -1.14 | -1.14 | 8.10 | 1.37 | 1.36 | -- | 30.39 | 272,062.20 | -18.92 | 4.32 | -30.06 | 6.05 | 90.70 | 90.28 | -13.95 | 3.68 | -- | 1,593.99 | 0.0022 | -- | 16.24 | 26.27 | -1,656.09 | -- | 35.09 | -- |
| Biodesix Inc | 65.56m | -43.82m | 174.56m | 217.00 | -- | 6.27 | -- | 2.66 | -0.3941 | -0.3941 | 0.5663 | 0.1915 | 0.6918 | -- | 9.49 | 302,129.00 | -46.24 | -55.60 | -60.89 | -80.94 | 77.72 | 59.53 | -66.84 | -105.15 | -- | -3.91 | 0.5647 | -- | 28.46 | 19.16 | 20.32 | -- | 106.31 | -- |
| American Oncology Network Inc | 1.59bn | -14.57m | 179.17m | 1.53k | -- | -- | -- | 0.1125 | -1.72 | -1.72 | 94.45 | -2.42 | 4.04 | 34.64 | 11.68 | 1,044,447.00 | -13.15 | -- | -- | -- | 5.27 | -- | -3.26 | -- | 1.11 | -9.60 | 0.6406 | -- | 11.27 | -- | -- | -- | -- | -- |
| ModivCare Inc | 2.79bn | -183.04m | 249.54m | 21.20k | -- | -- | -- | 0.0895 | -12.87 | -12.87 | 196.11 | -1.19 | 1.63 | -- | 8.07 | 131,491.50 | -10.35 | -1.36 | -15.25 | -1.83 | 15.52 | 17.58 | -6.34 | -0.9619 | -- | 0.2753 | 1.01 | -- | 9.85 | 14.71 | -542.83 | -- | 19.27 | -- |
| Holder | Shares | % Held |
|---|---|---|
| Telemark Asset Management LLCas of 30 Sep 2024 | 8.28m | 5.71% |
| AIGH Capital Management LLCas of 30 Sep 2024 | 5.68m | 3.91% |
| Farallon Capital Management LLCas of 30 Sep 2024 | 4.64m | 3.19% |
| Sio Capital Management LLCas of 30 Sep 2024 | 4.34m | 2.99% |
| Soleus Capital Management LP (Investment Management)as of 30 Sep 2024 | 4.04m | 2.78% |
| Opaleye Management, Inc.as of 30 Sep 2024 | 3.82m | 2.63% |
| SilverArc Capital Management LLCas of 30 Sep 2024 | 3.56m | 2.45% |
| Monashee Investment Management LLCas of 30 Sep 2024 | 3.50m | 2.41% |
| The Vanguard Group, Inc.as of 30 Sep 2024 | 2.94m | 2.03% |
| Birchview Capital LPas of 05 Nov 2024 | 2.70m | 1.86% |
